- Home
- LZB vs IMCR Comparison
LZB vs IMCR Comparison
Compare LZB & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZB
- IMCR
- Stock Information
- Founded
- LZB 1927
- IMCR 2008
- Country
- LZB United States
- IMCR United Kingdom
- Employees
- LZB N/A
- IMCR N/A
- Industry
- LZB Home Furnishings
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LZB Consumer Discretionary
- IMCR Health Care
- Exchange
- LZB Nasdaq
- IMCR Nasdaq
- Market Cap
- LZB 1.7B
- IMCR 1.5B
- IPO Year
- LZB N/A
- IMCR 2021
- Fundamental
- Price
- LZB $38.13
- IMCR $31.34
- Analyst Decision
- LZB Buy
- IMCR Buy
- Analyst Count
- LZB 2
- IMCR 10
- Target Price
- LZB $46.00
- IMCR $58.13
- AVG Volume (30 Days)
- LZB 489.2K
- IMCR 560.7K
- Earning Date
- LZB 06-17-2025
- IMCR 08-07-2025
- Dividend Yield
- LZB 2.31%
- IMCR N/A
- EPS Growth
- LZB N/A
- IMCR N/A
- EPS
- LZB 2.35
- IMCR N/A
- Revenue
- LZB $2,109,207,000.00
- IMCR $333,581,000.00
- Revenue This Year
- LZB $3.83
- IMCR $26.82
- Revenue Next Year
- LZB $3.88
- IMCR $8.15
- P/E Ratio
- LZB $16.19
- IMCR N/A
- Revenue Growth
- LZB 3.04
- IMCR 25.75
- 52 Week Low
- LZB $35.18
- IMCR $23.15
- 52 Week High
- LZB $48.31
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- LZB 35.05
- IMCR 40.28
- Support Level
- LZB $37.78
- IMCR $35.10
- Resistance Level
- LZB $40.05
- IMCR $37.56
- Average True Range (ATR)
- LZB 1.02
- IMCR 1.74
- MACD
- LZB -0.36
- IMCR -0.79
- Stochastic Oscillator
- LZB 8.73
- IMCR 0.75
About LZB La-Z-Boy Incorporated
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; and Retail, which sells upholstered and case goods furniture to the end consumer. The majority of the company's revenue is derived from its Wholesale segment.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.